Nicholas Chua
University of Technology MARA (UiTM), Malaysia
Title: Procedural safety and one month outcome of patients treated with magnesium bioresorbable scaffold
Biography
Biography: Nicholas Chua
Abstract
Background: Magnesium Bioresorbable Scaffold (BRS) was launched last year. The advantage of using BRS include, reduced long-term complications such as stent fracture, late stent thrombosis and in-stent restenosis with return of normal vasomotor function and late lumen gain with plaque regression. However, procedural safety and long-term outcome data is scarce.
Objective: The objective of the study is to identify safety and outcome of patients undergoing Percutaneous Coronary Intervention (PCI) with magnesium BRS.
Materials & Methods: This was a prospective, observational single center study conducted in UiTM Sungai Buloh from 1st November 2016 to 14th February 2017.
Results: 7 patients who were enrolled had mean age of 46 (±9). All were male. Ethnicity breakdown showed 5 Malays, 1 Chinese and 1 Indian. Cardiovascular risk assessment revealed 85.7% diabetes mellitus, 42.9% smokers, 28.6% hypertension and 28.6% dyslipidemia. Target vessels treated were 6 left anterior descending (LAD) and 1 right coronary artery (RCA). Out of the 7 patients, 28.6% were type A lesions, 42.8% were type B1 and 28.5% were type C. Among those, 4 involved LAD-D1 bifurcations and 2 were Chronic Total Occlusions (CTO). The lesions were prepared with semi-compliant balloons in 5 cases and non-compliant balloons in 2 cases. The balloon-to-stent ratio were 1:1 (n=1), 0.92:1 (n=1), 0.85:1 (n=4) and 0.83:1 (n=1). The magnesium BRS diameters used were 3.5 mm (n=4) and 3.0 mm (n=3) with length of 15 mm (n=1), 20 mm (n=4) and 25 mm (n=2). Post-dilatation in one patient was carried out with non-compliant balloon of equal diameter to the stent, while the rest had upsizing with +0.5 mm larger balloons. Procedural outcome was 100% successful. At one-month follow-up, there were no symptoms, MACE or TLR.
Conclusions: We demonstrated safety and good short-term outcome in the use of magnesium BRS in our cohort. However, larger cohort and long-term outcome monitoring would better delineate the safety and efficacy of this BRS.